SNRI duloxetine alleviated asthma symptoms through anti-inflammatory and antioxidative responses regulated by the PI3K/AKT/mTOR and Nrf2/HO-1 signaling pathways [133] and protected human neuroblastoma cells from oxidative stress-induced cell death through the Akt/Nrf-2/HO-1 pathway [134]. Here, NFE2L2 is linked to asthma.